<qa>  What is a multicenter, randomized, double-blind, placebo-controlled,Multicenter, randomized, double-blind, placebo-controlled, 5-arm, dose-ranging study to assess the efficacy of subcutaneous injections of Golimumab CNTO 148, 50 or 100 mg, at either 2- or 4- week intervals in subjects with active RA despite MTX therapy. 